Anecortave Acetate Versus Placebo in AMD Patients Following PDT

Alcon

Status and phase: Completed; Phase 2

Conditions: AMD

Treatments: Drug: anecortave acetate

Study type: Interventional

Funder types: Industry

Identifiers

NCT00346866

C-00-07

Details and patient eligibility

About

The purpose of this study was to evaluate the efficacy of anecortave acetate for depot suspension (30 mg and 15 mg) plus PDT versus PDT alone with respect to maintenance of visual acuity in patients with wet AMD.

Sex: All

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• AMD disease

Exclusion criteria

• Age

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind